Page 1 | Search Results | Blood | American Society of Hematology

1-16 of 16

Sort by

Sort Order Select

Journal Articles

Survival and Treatment Response in CTCL Can be Predicted Using Volumetric Lymph Node Size and Dynamic Changes in Lymph Node Size and Skin Score

Alexander Kaminsky, Lauren M. Fahmy, Zaid Bilgrami, Hye Ryung Yang, Volkan Beylergil, Mengxi Zhou, Antonio T. Fojo, Susan E. Bates, Lawrence Schwartz, Larisa J Geskin

Blood (2024) 144 (Supplement 1): 4446.

https://doi.org/10.1182/blood-2024-211442

Published: 2024

Journal Articles

Staphylococcus aureus induces drug resistance in cancer T cells in Sézary syndrome

Blood (2024) 143 (15): 1496–1512.

https://doi.org/10.1182/blood.2023021671

Published: 2024

Includes: Supplemental data

Journal Articles

Dynamic Changes in Lymph Node Size and Skin Scoring Predict Response to Treatment in CTCL: An Interim Analysis

Lauren M. Fahmy, Hye Ryung Yang, Mengxi Zhou, Volkan Beylergil, Celine M. Schreidah, Zaid Bilgrami, Bradley D. Kwinta, Lawrence Schwartz, Antonio T. Fojo, Susan E. Bates, Larisa J. Geskin

Blood (2023) 142 (Supplement 1): 4443.

https://doi.org/10.1182/blood-2023-189493

Published: 2023

Journal Articles

Umbralisib/TGR-1202 As a Novel Dual PI3K/CK1 Inhibitor Has a Unique Therapeutic Role in Silencing Oncogenes in Aggressive Lymphomas

Ipsita Pal, PhD, Yu Ri Kim, MD, Luigi Scotto, PhD, Mark R Lipstein, PhD, Abdullah Mahmood Ali, PhD, Siddhartha Mukherjee, MD PhD, Susan E. Bates, MDPhD, Owen A. O'Connor, MD, PhD, Changchun Deng, MD PhD

Blood (2017) 130 (Supplement 1): 2809.

https://doi.org/10.1182/blood.V130.Suppl_1.2809.2809

Published: 2017

Journal Articles

Romidepsin Is Effective and Well-Tolerated In Patients ≥ 60 Years Old With Relapsed Or Refractory Peripheral T-Cell Lymphoma (PTCL): Analysis From Phase 2 Trials

Andrei R. Shustov, MD, Bertrand Coiffier, MD, PhD, Steven M. Horwitz, MD, Lubomir Sokol, MD, Ph.D, Barbara Pro, MD, Tina Nielsen, MD, PhD, Julie Wolfson, MPH, Barbara E Balser, VMD, Robin Eisch, RN, Leslie Popplewell, MD, Miles Prince, MD, FRACP, FRCPA, Steven L. Allen, M.D., Richard Piekarz, MD, PhD, Susan E. Bates, MD

Blood (2013) 122 (21): 4385.

https://doi.org/10.1182/blood.V122.21.4385.4385

Published: 2013

Journal Articles

MAPK pathway activation leads to Bim loss and histone deacetylase inhibitor resistance: rationale to combine romidepsin with an MEK inhibitor

Arup R. Chakraborty, Robert W. Robey, Victoria L. Luchenko, Zhirong Zhan, Richard L. Piekarz, Jean-Pierre Gillet, Andrew V. Kossenkov, Julia Wilkerson, Louise C. Showe, Michael M. Gottesman, Nathan L. Collie, Susan E. Bates

Blood (2013) 121 (20): 4115–4125.

https://doi.org/10.1182/blood-2012-08-449140

Published: 2013

Includes: Supplemental data

Journal Articles

Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma

Blood (2011) 117 (22): 5827–5834.

https://doi.org/10.1182/blood-2010-10-312603

Published: 2011

Journal Articles

Epigenetic Modulation and Therapy of Lymphoid Malignancies

Susan E. Bates, MD

Blood (2010) 116 (21): SCI-30.

https://doi.org/10.1182/blood.V116.21.SCI-30.SCI-30

Published: 2010

Journal Articles

In Vitro and In Vivo Inhibition of P-Glycoprotein (ABCB1) by a Novel Non-Substrate Compound: HG-829

Gisela Caceres, Ph.D., Robert W Robey, Ph.D., Lubomir Sokol, MD, PhD, Kathy Rocha McGraw, William J Fulp, Justine Clark, MS, Nicholas J Lawrence, Ph.D., Said Sebti, Ph.D., Susan E. Bates, MD, Alan F. List

Blood (2010) 116 (21): 3986.

https://doi.org/10.1182/blood.V116.21.3986.3986

Published: 2010

Journal Articles

Phase II Trial of Romidepsin, FK228, in Cutaneous and Peripheral T-Cell Lymphoma: Clinical Activity and Molecular Markers.

Richard L. Piekarz, MD PhD, Robin Frye, RN, Maria Turner, MD, John Wright, MD, PhD, Steven Allen, MD, Mark H. Kirschbaum, MD, Jasmine Zain, MD, Miles Prince, MD, Laura Hutchins, MD, Louise C. Showe, PhD, William D. Figg, PharmD, Tito Fojo, MD, PhD, Susan E. Bates, MD, for All Collaborators

Blood (2006) 108 (11): 2469.

https://doi.org/10.1182/blood.V108.11.2469.2469

Published: 2006

Journal Articles

Completion of the First Cohort of Patients with Cutaneous T-Cell Lymphoma Enrolled on a Phase II Trial of Depsipeptide.

Richard L. Piekarz, MD, PhD, Robin Frye, RN, Maria Turner, MD, John Wright, MD, PhD, Steven Allen, MD, Mark H. Kirschbaum, MD, Jasmine Zain, MD, Miles Prince, MD, Susan E. Bates, MD, for All Collaborators

Blood (2005) 106 (11): 231.

https://doi.org/10.1182/blood.V106.11.231.231

Published: 2005

Journal Articles

T-cell lymphoma as a model for the use of histone deacetylase inhibitors in cancer therapy: impact of depsipeptide on molecular markers, therapeutic targets, and mechanisms of resistance

Richard L. Piekarz, Robert W. Robey, Zhirong Zhan, Ganesh Kayastha, Anousheh Sayah, Amina H. Abdeldaim, Sonia Torrico, Susan E. Bates

Blood (2004) 103 (12): 4636–4643.

https://doi.org/10.1182/blood-2003-09-3068

Published: 2004

Journal Articles

Expression and activity of breast cancer resistance protein (BCRP) in de novo and relapsed acute myeloid leukemia

Dorina M. van der Kolk, Edo Vellenga, George L. Scheffer, Michael Müller, Susan E. Bates, Rik J. Scheper, Elisabeth G. E. de Vries

Blood (2002) 99 (10): 3763–3770.

https://doi.org/10.1182/blood.V99.10.3763

Published: 2002

Journal Articles

Inhibitor of histone deacetylation, depsipeptide (FR901228), in the treatment of peripheral and cutaneous T-cell lymphoma: a case report

Richard L. Piekarz, Rob Robey, Victor Sandor, Susan Bakke, Wyndham H. Wilson, Laila Dahmoush, Douglas M. Kingma, Maria L. Turner, Rosemary Altemus, Susan E. Bates

Blood (2001) 98 (9): 2865–2868.

https://doi.org/10.1182/blood.V98.9.2865

Published: 2001

Journal Articles

Genetic Polymorphism in MDR-1 : A Tool for Examining Allelic Expression in Normal Cells, Unselected and Drug-Selected Cell Lines, and Human Tumors

Lyn A. Mickley, Jong-Seok Lee, Zheng Weng, Zhirong Zhan, Manuel Alvarez, Wyndham Wilson, Susan E. Bates, Tito Fojo

Blood (1998) 91 (5): 1749–1756.

https://doi.org/10.1182/blood.V91.5.1749

Published: 1998

Journal Articles

Expression of the Multidrug Resistance-Associated Protein Gene in Refractory Lymphoma: Quantitation by a Validated Polymerase Chain Reaction Assay

Zhirong Zhan, Victor A. Sandor, Erick Gamelin, Joanna Regis, Bruce Dickstein, Wyndham Wilson, Antonio T. Fojo, Susan E. Bates

Blood (1997) 89 (10): 3795–3800.

https://doi.org/10.1182/blood.V89.10.3795

Published: 1997

NARROW

Survival and Treatment Response in CTCL Can be Predicted Using Volumetric Lymph Node Size and Dynamic Changes in Lymph Node Size and Skin Score

Staphylococcus aureus induces drug resistance in cancer T cells in Sézary syndrome

Dynamic Changes in Lymph Node Size and Skin Scoring Predict Response to Treatment in CTCL: An Interim Analysis

Umbralisib/TGR-1202 As a Novel Dual PI3K/CK1 Inhibitor Has a Unique Therapeutic Role in Silencing Oncogenes in Aggressive Lymphomas

Romidepsin Is Effective and Well-Tolerated In Patients ≥ 60 Years Old With Relapsed Or Refractory Peripheral T-Cell Lymphoma (PTCL): Analysis From Phase 2 Trials

MAPK pathway activation leads to Bim loss and histone deacetylase inhibitor resistance: rationale to combine romidepsin with an MEK inhibitor

Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma

Epigenetic Modulation and Therapy of Lymphoid Malignancies

In Vitro and In Vivo Inhibition of P-Glycoprotein (ABCB1) by a Novel Non-Substrate Compound: HG-829

Phase II Trial of Romidepsin, FK228, in Cutaneous and Peripheral T-Cell Lymphoma: Clinical Activity and Molecular Markers.

Completion of the First Cohort of Patients with Cutaneous T-Cell Lymphoma Enrolled on a Phase II Trial of Depsipeptide.

T-cell lymphoma as a model for the use of histone deacetylase inhibitors in cancer therapy: impact of depsipeptide on molecular markers, therapeutic targets, and mechanisms of resistance

Expression and activity of breast cancer resistance protein (BCRP) in de novo and relapsed acute myeloid leukemia

Inhibitor of histone deacetylation, depsipeptide (FR901228), in the treatment of peripheral and cutaneous T-cell lymphoma: a case report

Genetic Polymorphism in MDR-1 : A Tool for Examining Allelic Expression in Normal Cells, Unselected and Drug-Selected Cell Lines, and Human Tumors

Expression of the Multidrug Resistance-Associated Protein Gene in Refractory Lymphoma: Quantitation by a Validated Polymerase Chain Reaction Assay

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only